Table of Contents
The health systems and health plans that have pushed AI furthest into their operations are among the least equipped to prove what it is returning, according to a survey of 64 U.S. healthcare CFOs and finance leaders published Aug. 12 by Deloitte, revealing a striking healthcare CFOs AI value measurement gap across the industry.
The Core Healthcare CFOs AI Value Measurement Gap Deloitte Found
Only 18% of organizations Deloitte classified as “AI scalers” said they have mature financial attribution capabilities, meaning they consistently measure AI’s effect on revenue growth or cost savings with defined baselines and clear ownership of key performance indicators. Among “AI starters,” 31% reported that level of maturity.
How the Survey Was Conducted
The survey was conducted in spring 2026 among 32 finance leaders at health systems with more than $1 billion in revenue and 32 at health plans with more than 500,000 members. Forty-four percent qualified as AI scalers, defined as organizations where more than 33% of generative AI initiatives launched over the past two years reached scaled deployment across multiple functions. Deloitte said the labels were built for analytical comparison and do not represent a formal maturity model.
Why Investment Intent Outpaces This Healthcare CFOs AI Value Measurement Gap
Investment intent is highest among the organizations with the thinnest measurement discipline. Seventy-five percent of AI scalers said they plan to increase spending on generative and agentic AI over the next 12 months, compared with 67% of AI starters. Scalers are also more confident in payback, with 85% expecting AI investments to break even in less than five years, compared with 72% of starters.
Return Expectations Follow the Same Pattern
Sixty-four percent of scalers estimate annualized cost savings of 5% or more from AI within one to two years, compared with 45% of starters. On the revenue side, 75% of scalers expect annualized growth of 2% or more, compared with 63% of starters, a confidence gap that stands in tension with the measurement maturity gap Deloitte documented.
Why Most Organizations Sit in a Measurement Middle Tier
Most organizations sit in a middle tier of measurement. Sixty-eight percent of scalers said they rely primarily on before-and-after comparisons for some initiatives, compared with 56% of starters. Deloitte attributed the gap to the complexity of wider deployment: multiple teams shape the same outcome, baselines shift, and benefits show up indirectly or over longer time horizons.
How AI’s Cost Structure Complicates This Healthcare CFOs AI Value Measurement Challenge
AI’s cost structure is a second complication. Consumption is increasingly metered in tokens rather than licenses or seats, making a meaningful share of AI spending a variable input cost rather than fixed overhead. Deloitte said a use case can improve cycle time or productivity and still fail financially if prompts, retrieval, outputs, orchestration steps or agent-to-agent activity push costs up faster than benefits, a risk concentrated in high-volume workflows such as revenue cycle, contact centers, prior authorization, clinical documentation and member services.
Deloitte’s Recommended Value Ledger Framework
Deloitte recommends each AI use case carry a “value ledger” documenting the value driver, the baseline, the owner of the relevant KPIs, a consumption metric and a review cadence. It also suggests finance separate AI’s impact into what is directly attributable, what is reasonably contributory and what is not yet monetized, so leaders can recognize capacity gains without overclaiming savings. A prior authorization agent, for example, could be tracked on nurse review minutes avoided, approval turnaround time, avoidable-denial reduction and cost per authorization.
Why This Framework Addresses a Documented Gap
By explicitly separating directly attributable value from merely contributory or unmonetized impact, this value ledger approach directly targets the measurement complexity Deloitte identified as a core barrier, giving finance teams a structured way to build credible attribution even within multi-team, multi-workflow AI deployments.
How Public Messaging Mirrors This Healthcare CFOs AI Value Measurement Gap
Public messaging mirrors the internal gap. In a separate analysis of 17,622 newsroom and press release articles published by 62 health systems and health plans between January 2023 and May 2026, Deloitte reviewed 408 technology-focused pieces and found that narratives citing demonstrated value rose from 9% in 2023 to 19% in 2026. Expected value remained the dominant frame throughout, accounting for roughly 35% to 45% of coverage.
What Organizations Actually Cite When They Do Claim Results
When organizations did cite proven results, they more often pointed to operational or clinical improvement than to cost savings, revenue growth or margin gains, suggesting that even among the minority of organizations willing to publicly claim demonstrated AI value, quantifiable financial metrics remain harder to substantiate than qualitative operational gains.
Why This Healthcare CFOs AI Value Measurement Gap Matters Now
The findings come as CFOs weigh AI against competing capital demands and prepare for Medicaid funding cuts that begin phasing in after 2026, a stretch in which every dollar of technology spending is likely to draw sharper board scrutiny. As Deloitte put it: “Momentum may justify initial investment. Sustained investment will involve evidence.”
What This Means for Organizations Still Scaling AI
Given that Medicaid funding pressure is set to intensify board-level financial scrutiny at precisely the moment AI scalers are simultaneously most invested and least equipped to prove returns, healthcare finance leaders may face growing pressure to close this measurement gap quickly rather than continuing to rely on before-and-after comparisons or expected-value framing.
What This Healthcare CFOs AI Value Measurement Report Means Going Forward
With 75% of AI scalers planning to increase spending despite only 18% having mature attribution capabilities, this report suggests healthcare organizations are largely operating on momentum and confidence rather than demonstrated financial evidence when it comes to AI investment decisions. Given Deloitte’s explicit warning that sustained investment will require evidence, CFOs at organizations further along in AI deployment may need to prioritize building value ledger frameworks now, before Medicaid funding cuts intensify the scrutiny their AI spending will face.
What to Watch Going Forward
As Medicaid funding cuts begin phasing in after 2026, industry observers will likely watch whether health systems and health plans close this measurement gap quickly enough to defend continued AI investment under sharper board scrutiny. Given the persistent disconnect between public messaging emphasizing expected value and the still-developing internal capability to measure actual financial returns, this healthcare CFOs AI value measurement challenge may become an increasingly consequential factor in determining which organizations sustain their AI investment pace and which pull back as the broader industry’s capital environment tightens.
For more healthcare industry updates, insights and news, visit DistilINFO. Click here to subscribe to stay informed.
